Previous 10 | Next 10 |
As the demand for a COVID-19 vaccine or a treatment is on the rise with the number of coronavirus cases increasing each passing day, Alexion Pharmaceuticals (ALXN), BioNTech (BNTX), and Ultragenyx Pharmaceutical (RARE) should benefit significantly because of the progress they made so far with...
Ultragenyx Pharmaceutical (RARE) has announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts, thus enabling in-house manufacturing of the Company’s pipeline of clinical stage adeno-associated virus-based gene thera...
State-of-the-art facility to be located in Bedford, Massachusetts NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ...
The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep with the broad market rally.Big Biopharma leaders: Eli Lilly ([[LLY]] +14.6%), AbbVie ([[ABBV]] +9.4...
NOVATO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the closing of its previously anno...
Ultragenyx Pharmaceutical (RARE) commences an underwritten public offering of up to $400M of shares of its common stock. Underwriters 30-day option to purchase up to an additional $60M of shares at the public offering price, less the underwriting discount.Press Release For further deta...
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2020 Earnings Conference Call October 27, 2020 17:00 ET Company Participants Joshua Higa - Investor Relations Emil Kakkis - Chief Executive Officer and President Camille Bedrosian - Chief Medical Officer Erik Harris - Chief Commercial Officer Mardi Die...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q3 2020 Earnings Call Oct 27, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Tr...
Tonix Pharmaceuticals provides updates for fibromyalgia and COVID-19 studies. Innate Pharma proceeds with monalizumab trial, triggering milestone payment. Ultragenyx inks deal with Solid Biosciences for Duchenne Muscular Dystrophy program. For further details see: Tonix ...
Ultragenyx Pharmaceutical (RARE): Q3 GAAP EPS of -$1.13 beats by $0.15.Revenue of $81.5M (+215.9% Y/Y) beats by $25.66M.Press Release For further details see: Ultragenyx Pharmaceutical EPS beats by $0.15, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...